Merck's recall of rofecoxib - A strategic perspective

Article Abstract:

The effects of Merck, a pharmaceutical company at the time of the voluntary withdrawal of its acute-pain medication, rofecoxib on September 30, 2004 and on November 1, 2004, on its market shares are analyzed. Although the newspapers allegations on this led to investors reacting harshly, Merck is attempting to convince the public that it cares about patients' safety, so its long-term strategic challenge is to turn scientific expertise into competitive advantage.

United States, Pharmaceutical preparations, Product defects and recalls, Pharmaceutical industry, Merck & Company Inc., Rofecoxib (Medication)

---

Cost-effectiveness of cervical-cancer screening in five developing countries

Article Abstract:

Computer-based models are used to assess the cost-effectiveness of a variety of cervical-cancer screening strategies in India, Kenya, Peru, South Africa, and Thailand. Cervical-cancer screening strategies incorporating visual inspection of the cervix with acetic acid or DNA testing for HPV in one or two clinical visits are cost-effective alternatives to conventional three-visit cytology-based screening programs in resource-poor settings.

New England States, Economic aspects, New England

---

How often should we screen for cervical cancer?

Article Abstract:

Women who have had three negative Pap tests can probably begin having Pap tests every three years rather than every year. A study published in 2003 showed that these women have a very low risk of developing cervical cancer. Even though Pap tests are relatively cheap, testing millions of women every year would not be cost-effective if many of the women have a very low risk of developing cervical cancer.

Standards, Pap test

Similar abstracts:

• Abstracts: The nursing management of dyspnoea in palliative care. Issues for clinical leaders in nursing development units
• Abstracts: Fixed and dynamic predictors of client retention in therapeutic communities
• Abstracts: Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies
• Abstracts: Lyme disease vaccines. Cost-effectiveness of pneumococcal vaccine for people 50 through 64 years of age. A need to update and revise the pneumococcal vaccine recommendations for adults
• Abstracts: Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.